GSK plc
LSEGSK is the quiet outperformer in a difficult week for large-cap pharma — up 2.4% while most of its closest peers fell — and the question worth sitting with is whether that relative strength reflects genuine conviction or simply a thinner short book unwinding. The positioning story is emphatically not about short pressure. Short interest is negligible at well under 1% of free float…
Snapshot as of 22 Jun 2026
GSK is the quiet outperformer in a difficult week for large-cap pharma — up 2.4% while most of its closest peers fell — and the question worth sitting with is whether that relative strength reflects genuine conviction…
GSK heads into its July 28 Q2 results on a quiet improving trend — shares up 3% this week and 4.4% over the past month, while short sellers have reduced positions to their smallest level in over six weeks. The most…
GSK enters its Q1 2026 results on April 29 carrying a stock down 6% on the week and a short book that has quietly unwound heading into the print. The most telling positioning signal is how dramatically short sellers…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for GSK — free to start on ORTEX.
Sign up for free →Open GSK on ORTEX